<DOC>
	<DOC>NCT01411423</DOC>
	<brief_summary>This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have been administered with Nexavar for unresectable or advanced renal cell carcinoma (RCC). The objective of this study is to assess safety and effectiveness of Nexavar under real-life practice conditions. This study is an all case investigation of which the enrollment period is 15 months, and all patients who received Nexavar will be recruited and followed one year since starting Nexavar administration.</brief_summary>
	<brief_title>Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients who received Nexavar for unresectable or advanced renal cell carcinoma Patients who are contraindicated based on the product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Nexavar</keyword>
	<keyword>Unresectable or advanced renal cell carcinoma</keyword>
</DOC>